Sep 17, 2025 • Benzinga
NEUTRAL
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials - Johnson & Johnson ( NYSE:JNJ )
Icotrokinra outperformed deucravacitinib in skin clearance at Weeks 16 and 24 with similar or fewer adverse events. At Week 52, 86% of adolescents on icotrokinra achieved PASI 90 response, showing sustained effectiveness. Up Next: Wall Street trader's 34-0 strategy goes public this week.
Sep 17, 2025 • Benzinga
SOMEWHAT-BULLISH
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Biohaven ( NYSE:BHVN ) , Avient ( NYSE:AVNT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Sep 12, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
Sep 12, 2025 • Benzinga
SOMEWHAT-BULLISH
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Protagonist Therapeutics ( NASDAQ:PTGX ) , StandardAero ( NYSE:SARO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Mayank Mamtani initiated coverage on Theravance Biopharma, Inc.
Aug 07, 2025 • Motley Fool
NEUTRAL
Protagonist ( PTGX ) Q2 Revenue Falls 26%
Protagonist Therapeutics ( NASDAQ:PTGX ) , a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025. The most significant news from the release was the company's continued advancement of its ...
Aug 06, 2025 • Zacks Commentary
NEUTRAL
Protagonist Therapeutics ( PTGX ) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?